CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC®...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weekssNDA filed in US, China and Japan; decisions expected H2 2026Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026. Results show that patients treated with Pluvicto experienced a higher frequency and depth of PSA response when combined with SoC (androgen receptor pathway...

Eimskip and Faroe Ship have received a notice from the Seafarers’ Union of Iceland (SÍ) announcing an indefinite strike by bosuns and able seamen on the Company’s own vessels Brúarfoss, Dettifoss, and Selfoss, effective from 12:00 PM on Monday, May 25, if an agreement hasn´t been reached before that time. The agreement with SÍ members on the Company’s own vessels expired at the end of last year. During the validity period, the agreement has changed in line with general labor market wage increases under the so-called stability agreement, as well as additional increases agreed for these roles. SÍ had previously announced a temporary strike on the Company’s own vessels scheduled for April 12.-15. which was withdrawn on April 8. A temporary strike by harbor employees, originally announced for April 13, was postponed until the period of May...

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) —  NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response...

MIAMI, FL, May 17, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced it will host a conference call on Monday, May 18, 2026 at 9:00 a.m. Eastern Time to discuss its first quarter 2026 financial results and provide a corporate update. This release corrects a previously issued announcement to reflect updated conference call details. Conference Call Details •  Date: Monday, May 18, 2026 •  Time: 9:00 a.m. Eastern Time •  Participant Dial-In (U.S. Toll-Free): 877-407-9219 / +1 412-652-1274 •  Participant Dial-In (International): +1 412-652-1274 (additional international numbers available at www.incommconferencing.com/international-dial-in) •  Participant Dial-In (Canada Toll-Free): 877-407-9219 / +1 412-652-1274 Webcast...

TORONTO, May 16, 2026 (GLOBE NEWSWIRE) — VVC Exploration Corporation, dba VVC Resources (“VVC” or the “Company”) (TSX-V: VVC and OTCQB: VVCVF) announces that it has applied to the Ontario Securities Commission (the “OSC”), as its principal regulator, for a Management Cease Trade Order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). This application follows an anticipated delay in filing the Company’s audited annual financial statements, management’s discussion and analysis, and related officer certifications for the fiscal year ended January 31, 2026 (collectively, the “Required Filings”), which are due on June 1, 2026. Reason for Anticipated DefaultThe delay in completing the Required Filings is a direct result of recent material corporate...

LONDON, May 16, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE:NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that its Board of Directors has approved a 3-year share repurchase program pursuant to which the Company may repurchase up to $500 million of nVent shares effective on July 23, 2026. The program is in addition to nVent’s existing authorization approved in July 2024, which expires July 23, 2027. nVent has approximately $96 million remaining under the July 2024 authorization. As of March 31, 2026, the company had approximately 162 million common shares outstanding. The authorization does not constitute a commitment to repurchase shares. The Company may conduct the repurchases through open market purchases, block trades and unsolicited negotiated transactions, pursuant...